Answers are grounded in this paper and cite their sources.
Despite the expanding global occurrence of neurological disorders, achieving the effective and sufficient delivery of therapeutic drug molecules to the central nervous system (CNS) continues to pose a considerable impediment. The brain's protective mechanisms, including the cerebrospinal fluid (CSF) and blood-brain barrier (BBB), hinder the passage of large lipophilic and hydrophilic molecules, thereby reducing the efficiency of conventional drug delivery approaches. As a non-invasive alternative, intranasal delivery has gained attention for its capability to evade the BBB and transport medications efficiently to the brain, though its efficacy remains reliant on the unique physiological characteristics of the nasal cavity. This review puts emphasis on nanotechnology-based nose-to-brain drug delivery techniques, which have shown significant potential in addressing these challenges. Various approaches, including the application of nano-carriers like liposomes, polymeric nanoparticles, lipid nanoparticles and nanoemulsions, are discussed for their ability to enhance bioavailability, improve permeability, facilitate BBB traversal, extend drug retention in the body, and enable targeted delivery to the brain, offering promising advancements in the therapy of neurological disorders.
No takes yet. Share an insight, caveat, or question.
Saxena et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: